Dermatological drugs are a category of medications used to treat a wide range of skin conditions, including acne, eczema, psoriasis, fungal infections, and dermatitis. These drugs are formulated to ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

NK cell therapy is gaining momentum as a promising solution to unmet medical needs in cancer treatment, offering safer, tar ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

The Dow Jones Industrial Average surged over 300 points on Monday, closing at a new all-time high as the post-election rally continued to gain momentum.

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Stocks rose for a fifth straight session, Bitcoin topped $87,000 and the dollar hit a one-year high, with investors continuing to bet those trades will benefit from President-elect Donald Trump’s ...

Bristol-Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Shares were recently up 11% after AbbVie reported ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company ...